Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
Colorcon
Boehringer Ingelheim
Baxter
McKesson

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Dasotraline

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Dasotraline: Patents, clinical trial progress, indications

Dasotraline is an investigational drug.

There have been 12 clinical trials for Dasotraline. The most recent clinical trial was a Phase 3 trial, which was initiated on March 31st 2017.

The most common disease conditions in clinical trials are Attention Deficit Disorder with Hyperactivity, Hyperkinesis, and Disease. The leading clinical trial sponsors are Sunovion and [disabled in preview].

There are nineteen US patents protecting this investigational drug and ninety international patents.

Recent Clinical Trials for Dasotraline
TitleSponsorPhase
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.SunovionPhase 3
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating DisorderSunovionPhase 3
Study of the What the Body Does to the Drug in Subjects With Mild, Moderate, and Severe Liver DysfunctionSunovionPhase 1

See all Dasotraline clinical trials

Clinical Trial Summary for Dasotraline

Top disease conditions for Dasotraline
Top clinical trial sponsors for Dasotraline

See all Dasotraline clinical trials

US Patents for Dasotraline

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Dasotraline   Start Trial Preparation of chiral amides and amines SUNOVION PHARMACEUTICALS INC. (Marlborough, MA)   Start Trial
Dasotraline   Start Trial Dosage of dasotraline and method for treatment of ADHD SUNOVION PHARMACEUTICALS INC. (Marlborough, MA)   Start Trial
Dasotraline   Start Trial Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine SUNOVION PHARMACEUTICALS INC. (Marlborough, MA)   Start Trial
Dasotraline   Start Trial Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide Sepracor Inc. (Marlborough, MA)   Start Trial
Dasotraline   Start Trial Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide Sepracor Inc. (Marlborough, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Dasotraline

Drugname Country Document Number Estimated Expiration Related US Patent
Dasotraline Australia 2007233041 2026-03-31   Start Trial
Dasotraline Canada 2648121 2026-03-31   Start Trial
Dasotraline China 101421228 2026-03-31   Start Trial
Dasotraline China 103588659 2026-03-31   Start Trial
Dasotraline Denmark 2013835 2026-03-31   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
McKesson
Mallinckrodt
Express Scripts
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.